title: Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome.
abstract: Previous studies from this laboratory have demonstrated a statistically significant dysregulation in several key components of the 2',5'-oligoadenylate (2-5A) synthetase/RNase L and PKR antiviral pathways in chronic fatigue syndrome (CFS) (Suhadolnik et al. Clin Infect Dis 18, S96-104, 1994; Suhadolnik et al. In Vivo 8, 599-604, 1994). Two methodologies have been developed to further examine the upregulated RNase L activity in CFS. First, photoaffinity labeling of extracts of peripheral blood mononuclear cells (PBMC) with the azido 2-5A photoaffinity probe, [32P]pApAp(8-azidoA), followed by immunoprecipitation with a polyclonal antibody against recombinant, human 80-kDa RNase L and analysis under denaturing conditions. A subset of individuals with CFS was identified with only one 2-5A binding protein at 37 kDa, whereas in extracts of PBMC from a second subset of CFS PBMC and from healthy controls, photolabeled/immunoreactive 2-5A binding proteins were detected at 80, 42, and 37 kDa. Second, analytic gel permeation HPLC was completed under native conditions. Extracts of healthy control PBMC revealed 2-5A binding and 2-5A-dependent RNase L enzyme activity at 80 and 42 kDa as determined by hydrolysis of poly(U)-3'-[32P]pCp. A subset of CFS PBMC contained 2-5A binding proteins with 2-5A-dependent RNase L enzyme activity at 80, 42, and 30 kDa. However, a second subset of CFS PBMC contained 2-5A binding and 2-5A-dependent RNase L enzyme activity only at 30 kDa. Evidence is provided indicating that the RNase L enzyme dysfunction in CFS is more complex than previously reported.
authors.affiliation: Department of Biochemistry, Temple University School of Medicine, Philadelphia, PA, USA.
authors.forename: R J
authors.initials: RJ
authors.lastname: Suhadolnik
authors.forename: D L
authors.initials: DL
authors.lastname: Peterson
authors.forename: K
authors.initials: K
authors.lastname: O'Brien
authors.forename: P R
authors.initials: PR
authors.lastname: Cheney
authors.forename: C V
authors.initials: CV
authors.lastname: Herst
authors.forename: N L
authors.initials: NL
authors.lastname: Reichenbach
authors.forename: N
authors.initials: N
authors.lastname: Kon
authors.forename: S E
authors.initials: SE
authors.lastname: Horvath
authors.forename: K T
authors.initials: KT
authors.lastname: Iacono
authors.forename: M E
authors.initials: ME
authors.lastname: Adelson
authors.forename: K
authors.initials: K
authors.lastname: De Meirleir
authors.forename: P
authors.initials: P
authors.lastname: De Becker
authors.forename: R
authors.initials: R
authors.lastname: Charubala
authors.forename: W
authors.initials: W
authors.lastname: Pfleiderer
mesh_terms: D015088:2',5'-Oligoadenylate Synthetase / Q000378:metabolism*; D000328:Adult; D000918:Antibody Specificity; D002352:Carrier Proteins; D016022:Case-Control Studies; D004722:Endoribonucleases / Q000276:immunology / Q000378:metabolism*; D015673:Fatigue Syndrome, Chronic / Q000201:enzymology*; D005260:Female; D006801:Humans; D006868:Hydrolysis; D007963:Leukocytes, Mononuclear / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight; D011233:Precipitin Tests; D011994:Recombinant Proteins / Q000276:immunology; D015854:Up-Regulation
chemical_list: D002352:Carrier Proteins; D011994:Recombinant Proteins; D015088:2',5'-Oligoadenylate Synthetase; D004722:Endoribonucleases; C031956:2-5A-dependent ribonuclease